香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 I037 完成中國 II 期臨床試驗結果分析的公告》僅 供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2024 年 11 月 30 日 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生及王忠先生。 * 僅供識別 证券代码：601607 证券 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 I048 臨床試驗申請獲得受理的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2024 年 11 月 26 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生及王忠先生。 * 僅供識別 证券代码：601607 证券简称：上海医药 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司簡式權益變動報告書》《上海醫藥集團股份有限公司關 於股東權益變動的提示性公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2024 年 11 月 14 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生及王忠先生。 * 僅供識別 上海医药集 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第十五次會議決議公告》《上海醫藥集團 股份有限公司關於聘任高級管理人員的公告》、《上海醫藥集團股份有限公司獨立董事的獨立 意見》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2024 年 11 月 6 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生及王忠先生。 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） * 僅供識別 上 海 醫 藥 集 團 股 份 有 限 公 司 （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於己酮可可堿注射液通過仿製藥一致性評價的公告》 僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2024 年 11 月 5 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生及王忠先生。 证券代码：601607 证券简称：上海医 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （股份代碼：02607） （於中華人民共和國註冊成立的股份有限公司） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於注射用頭孢他啶通過仿製藥一致性評價的公告》僅 供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2024 年 11 月 1 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生及王忠先生。 * 僅供識別 证券代码：601607 证券简称：上海医药 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司 ） （股份代碼：02607） 關連交易 擬參與設立標的基金 合夥協議 董事會欣然宣佈，於2024年10月29日，本公司附屬公司上海生物醫藥前沿產業創新 中心擬訂立合夥協議，内容有關參與設立標的基金，據此，上海生物醫藥前沿產業 創新中心（作為有限合夥人）、國孚領航（作為有限合夥人）、奉賢生物科技（作 為有限合夥人）、奉浦實業（作為有限合夥人）、生命信使（作為有限合夥人）、 鄭效東先生（作為有限合夥人）、項金生先生（作為有限合夥人）、九旺投資（作 為有限合夥人）、安永投資（作為有限合夥人）、曹紅光先生（作為有限合夥 人）、上實資本（作為普通合夥人）及GP2（作為普通合夥人）將分別認購人民幣 250百萬元、人民幣100百萬元、人民幣40百萬元、人民幣30百 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( ) 於中華人民共和國註冊成立的股份有限公司 (股份代碼: 02607) 持續關連交易 續簽採購框架協議 續簽採購框架協議 於 2024 年 10 月 29 日，本公司與永發印務訂立期限自 2025 年 1 月 1 日起至 2025 年 12 月 31 日止為 期一年的採購框架協議，據此，永發印務集團將向本集團繼續提供藥品的印刷包裝材料。 香港上市規則之含義 鑒於上實集團為本公司及上海實業之控股股東，永發印務為上海實業之間接非全資附屬公司，永發 印務屬於本公司於上市規則第 14A.07 條項下之關連人士。因此，根據上市規則第 14A 章，於採購框 架協議項下與永發印務集團擬進行之交易將構成本公司的持續關連交易。 由於採購框架協議項下擬進行之交易的建議年度上限的最高適用百分比率（上市規則第 ...

Financial Performance - For the first nine months of 2024, the company achieved operating revenue of RMB 209.63 billion, a year-on-year increase of 6.14%[6] - The net profit attributable to shareholders for the same period was RMB 4.05 billion, reflecting a year-on-year growth of 6.78%[6] - The total operating revenue for the reporting period was approximately 70.22 billion RMB, an increase of 8.16% compared to the same period last year[12] - The net profit attributable to shareholders of the listed company was approximately 1.11 billion RMB, a decrease of 6.29% year-on-year[12] - The total profit for the first three quarters of 2024 was ¥6.64 billion, up from ¥6.52 billion in 2023, reflecting an increase of 1.9%[27] - Net profit attributable to shareholders of the parent company reached ¥4.05 billion in 2024, compared to ¥3.80 billion in 2023, marking a growth of 6.8%[27] - The company reported a total comprehensive income of ¥4.99 billion for the first three quarters of 2024, compared to ¥4.78 billion in 2023, an increase of 4.4%[29] Revenue Segmentation - The pharmaceutical manufacturing segment reported sales revenue of RMB 18.28 billion, a decline of 12.10% year-on-year, while the pharmaceutical commerce segment saw sales revenue of RMB 191.35 billion, an increase of 8.28%[6] - The sales revenue from the company's CSO contract promotion business reached approximately 6.1 billion RMB, representing a year-on-year increase of 176.3%[11] - The sales from the company's health equipment business amounted to approximately 32.6 billion RMB, showing a year-on-year growth of 11.9%[11] Cash Flow and Assets - The company reported a net cash inflow from operating activities of RMB 2.78 billion, up 20.87% year-on-year[6] - The net cash flow from operating activities was approximately 2.27 billion RMB, reflecting a significant increase of 241.50%[12] - The company's cash and cash equivalents increased to ¥33,822,817,448.38 from ¥30,517,706,443.04, reflecting a growth of approximately 7.6%[22] - Total assets at the end of the reporting period were approximately 223.74 billion RMB, an increase of 5.55% from the end of the previous year[13] - The total current assets amounted to ¥173,787,729,817.04, up from ¥162,433,862,348.46, representing an increase of about 6.9%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 67,642[20] - The top 10 shareholders collectively hold 1,978,000,000 shares, representing approximately 53.4% of the total shares[19] - The top shareholder, Shanghai Pharmaceutical Group, holds 716,516,039 shares, accounting for 19.34% of the total shares[19] Research and Development - As of the report date, the company has 60 new drug candidates in clinical application or subsequent clinical research stages, including 46 innovative drugs[6] - Research and development expenses increased to ¥1.62 billion in 2024 from ¥1.47 billion in 2023, marking an increase of 10.1%[26] - The company is advancing its traditional Chinese medicine strategy, with ongoing clinical research on six major products[9] Strategic Partnerships - The company signed a strategic cooperation agreement with Sartorius Group to focus on biopharmaceutical innovation incubation and transformation[7] - A strategic cooperation agreement was established with Shanghai Jiao Tong University and other institutions to explore cell therapy[8] Cost Management - The company is implementing cost reduction and efficiency enhancement measures in its pharmaceutical manufacturing operations[10] Investment Income - The company reported a significant increase in investment income by 509.78% during the reporting period[17] - Investment income from joint ventures and associates increased significantly to ¥447.83 million in the first three quarters of 2024, compared to ¥89.92 million in the same period of 2023, representing a growth of 396.5%[27] Financial Ratios - The weighted average return on net assets was 1.58%, a decrease of 0.17 percentage points compared to the previous year[12] - Basic and diluted earnings per share were both ¥1.09 in 2024, up from ¥1.03 in 2023, indicating a growth of 5.8%[29]

Financial Performance - The net profit attributable to shareholders for the first half of 2024 is approximately CNY 2.94 billion, with a proposed cash dividend of CNY 0.80 per 10 shares, totaling CNY 296.28 million, which accounts for 10.07% of the net profit[4]. - The company's operating revenue for the first half of the year reached ¥139.41 billion, an increase of 5.14% compared to ¥132.59 billion in the same period last year[23]. - Net profit attributable to shareholders was ¥2.94 billion, reflecting a growth of 12.72% from ¥2.61 billion year-on-year[23]. - The basic earnings per share increased to ¥0.79, up 11.27% from ¥0.71 in the previous year[25]. - The total assets of the company at the end of the reporting period were ¥221.34 billion, representing a 4.42% increase from ¥211.97 billion at the end of the previous year[23]. - The total amount of non-recurring gains and losses was ¥236.75 million, after accounting for tax effects and minority interests[26]. - The company reported a significant increase in long-term receivables, which rose by 161.71% to RMB 596.54 million from RMB 227.94 million year-on-year[61]. - The company’s total assets included RMB 62.10 billion in overseas assets, accounting for 2.81% of total assets[62]. Dividend and Share Capital - The total share capital as of June 30, 2024, is 3,703,523,491 shares, which will be used as the basis for the dividend distribution[4]. - The report does not include any capital reserve fund conversion into share capital for this reporting period[4]. - The company will not conduct a capital reserve transfer to increase share capital during this reporting period[129]. - A cash dividend of 0.80 yuan per 10 shares (including tax) is proposed for shareholders, based on a total share capital of 3,703,523,491 shares as of June 30, 2024[129]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company emphasizes the importance of risk awareness regarding future plans and development strategies[4]. - The company has implemented strict internal control measures to prevent losses from derivative trading, including clear approval processes and risk management protocols[76]. - The report highlights various risks associated with derivative investments, including market risk, credit risk, and operational risk[76]. Corporate Governance - The report confirms that all board members attended the board meeting, ensuring the accuracy and completeness of the financial report[6]. - The company strictly adheres to the corporate governance code as per the Hong Kong listing rules, although it currently does not meet the gender diversity requirement on the board[134]. - The audit committee has reviewed and approved the accounting treatment methods adopted in the 2024 half-year report[138]. - The company is actively seeking suitable candidates to comply with the gender diversity regulations in the board of directors[134]. Research and Development - The company invested RMB 1.404 billion in R&D, a year-on-year increase of 15.26%, accounting for 11.03% of industrial sales[46]. - The company has 64 new drug pipelines, including 50 innovative drugs, with several in critical research and clinical phases[46]. - The company is actively advancing its cell therapy industrial layout and has initiated clinical trials for its first CAR-T product, B019[45]. - The company is actively responding to the "Healthy China 2030" strategy by increasing innovation investments and optimizing its product offerings[29]. Market and Sales Performance - The pharmaceutical industry segment reported revenue of RMB 12.73 billion, a year-on-year decline of 13.37%, while the pharmaceutical commerce segment generated revenue of RMB 126.68 billion, a year-on-year increase of 7.45%[43]. - The sales amount of the CSO contract promotion business surged to approximately CNY 4 billion, representing a year-on-year increase of 172%[51]. - The sales of non-pharmaceutical businesses, including medical devices and health products, reached approximately CNY 21.8 billion, with a year-on-year growth of about 11.12%[51]. - The sales of health food products from Shanghai Shenyin Microecology Technology Co., Ltd. reached CNY 173 million, reflecting a year-on-year increase of 331%[55]. Investment and Financial Activities - Investment income surged by 223.81% to RMB 246.36 million, compared to a loss of RMB 198.99 million in the previous year[57]. - The company reported a total guarantee amount of 2,524,289,236.08 RMB, which accounts for 3.61% of the company's net assets[167]. - The company has a total of 870,850.00 RMB in credit business with a related party, with actual transactions amounting to 209,257.89 RMB[165]. - The company’s total loan amount from a related party was 209,257.89 RMB during the reporting period[165]. Employee and Stock Options - Shanghai Pharmaceuticals employed 49,234 staff as of June 30, 2024, including 1,674 R&D personnel, focusing on enhancing employee performance and compensation linked to company performance[93]. - The company has implemented an employee stock option incentive plan, with various phases of stock options being exercised as per the announcements[130][132]. - The stock options granted to middle management and core personnel accounted for 77.911% of the total options granted[101]. - The total number of stock options granted under the incentive plan is 24.35572 million, accounting for no more than 1% of the total shares issued by the company as of the report date[3]. Environmental Responsibility - In 2024, the company signed environmental protection responsibility agreements with 20 subsidiaries, enhancing accountability for environmental management[140]. - The group issued a notice outlining six key energy management requirements, aiming to eliminate high-energy-consuming products and improve energy efficiency[141]. - A total of 65 energy-saving technical improvement projects are planned for 2024, with 35 projects completed by the end of the reporting period, expected to save RMB 7.09 million[141].